此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

研究晚期实体瘤患者静脉注射 QEQ278 的安全性和耐受性

2026年11月9日 更新者:Novartis Pharmaceuticals

QEQ278 在晚期实体瘤患者中的 I/Ib 期、开放标签、多中心研究

To characterize safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of QEQ278 in adult patients with advanced/metastatic non-small cell lung cancer, esophageal squamous cell carcinoma, renal cell carcinoma, and human papilloma virus associated head and neck squamous cell carcinoma.

研究概览

详细说明

This study is an open-label, phase I/Ib, multi-center study of QEQ278 as a single agent, consisting of a dose escalation part followed by a dose expansion part.

In the dose escalation part of the study, patients with non-small cell lung cancer (NSCLC), esophageal squamous cell carcinoma (ESCC), renal cell carcinoma (RCC), or human papilloma virus (HPV)-associated head and neck squamous cell carcinoma (HNSCC) will be treated with QEQ278 single agent until the maximum tolerated dose (MTD) is reached or a lower recommended dose (RD) is established.

The study may enter the dose expansion, after an MTD(s) and/or RD(s) is declared in the dose escalation.

研究类型

介入性

注册 (实际的)

30

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Taipei、台湾、10002
        • Novartis Investigative Site
      • Essen、德国、45147
        • Novartis Investigative Site
    • MI
      • Milan、MI、意大利、20133
        • Novartis Investigative Site
      • Singapore、新加坡、168583
        • Novartis Investigative Site
    • Chiba
      • Kashiwa、Chiba、日本、2778577
        • Novartis Investigative Site
      • Brussels、比利时、1200
        • Novartis Investigative Site
      • Paris、法国、75231
        • Novartis Investigative Site
    • California
      • Los Angeles、California、美国、90095
        • University of California LA
    • Florida
      • Fort Myers、Florida、美国、33901
        • Florida Cancer Specialists
    • Massachusetts
      • Boston、Massachusetts、美国、02114
        • Massachusetts General Hospital
      • Boston、Massachusetts、美国、02114
        • Massachusetts General Hospital Dept. of Mass General Hospital
      • Barcelona、西班牙、08035
        • Novartis Investigative Site

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 100年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Signed informed consent must be obtained prior to participation in the study.
  • Adult men and women ≥ 18 years of age.
  • Histologically confirmed and documented advanced malignancies (locally advanced malignancies, non-curable by surgery or radiotherapy and metastatic disease). Disease must be measurable, including presence of at least one measurable lesion, as determined by RECIST v1.1.
  • In the opinion of the treating investigator, patients must have received, but are not benefitting from standard therapies, be intolerant or ineligible to receive such therapy, or have no standard therapy option for the respective disease types (diseases listed below), as well as any other therapies deemed to be standard by local/institutional standard.
  • Non-small cell lung cancer
  • Esophageal squamous cell carcinoma
  • Renal cell carcinoma
  • HPV-associated head and neck squamous cell carcinoma
  • Must have a site of disease amenable to biopsy and be a candidate for tumor biopsy according to the treating institution's guidelines. The patient must be willing to undergo a new tumor biopsy at screening and during treatment.

Exclusion Criteria:

  • Active previously documented or suspected autoimmune disease. Patients with vitiligo, type I diabetes, residual hypothyroidism only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur should not be excluded. Patients previously exposed to anti-PD-1/PD-L1 treatment who are adequately treated for skin rash or with replacement therapy for endocrinopathies should not be excluded.
  • Patients with a history of or current interstitial lung disease or pneumonitis ≥ Grade 2.
  • Patients who discontinued prior anti-PD-1 therapy due to an anti-PD-1-related toxicity
  • Clinically significant cardiac disease or risk factors at screening
  • Insufficient bone marrow function at screening:
  • Infections:
  • Known history of testing positive for Human Immunodeficiency Virus infection.
  • Active Hepatitis B and / or Hepatitis C.
  • Active, documented COVID-19 infection
  • Known history of tuberculosis
  • Any serious uncontrolled infection (acute or chronic).
  • Systemic chronic steroid therapy (>10 mg/day prednisone or equivalent) or any immunosuppressive therapy, other than replacement-dose steroids in the setting of adrenal insufficiency, within 7 days of the first dose of study treatment. Topical, inhaled, and ophthalmic steroids are allowed.

Other protocol-defined inclusion/exclusion criteria may apply.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Part 1: Dose escalation

Dose escalation with QEQ278 single agent

Intravenous dosing of QEQ278

实验性的:Part 2: Dose expansion

Dose expansion with QEQ278 single agent

Intravenous dosing of QEQ278

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Incidence and nature of Dose Limiting Toxicities (DLTs) during the DLT evaluation period for single agent QEQ278
大体时间:28 days

A DLT is defined as an adverse event or abnormal laboratory value assessed as unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the DLT evaluation period and meets the criteria defined in the study protocol.

28 days
Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
大体时间:Up to 31 months

Incidence and severity of adverse events (AEs) and serious adverse events (SAEs), including changes in laboratory values, vital signs, and electrocardiograms (ECGs) qualifying and reported as AEs.

Up to 31 months
Frequency of dose interruptions, reductions
大体时间:Up to 30 months

Number of dose interruptions of QEQ278 and number of dose reductions of QEQ278

Up to 30 months
Dose intensity
大体时间:Up to 30 months

Dose intensity of QEQ278 is defined as the ratio of actual cumulative dose received and actual duration of exposure.

Up to 30 months

次要结果测量

结果测量
措施说明
大体时间
Overall response rate (ORR) per RECIST v1.1
大体时间:Up to 30 months

ORR is defined as the proportion of patients with a confirmed BOR of complete response (CR) or partial response (PR) by local investigator review as per RECIST v1.1.

Up to 30 months
Disease control rate (DCR) per RECIST v1.1
大体时间:Up to 30 months

DCR is defined as the proportion of patients with a confirmed best overall response (BOR) of CR or PR or stable disease (SD) by local investigator review as per RECIST v1.1.

Up to 30 months
Duration of Response (DOR) per RECIST v1.1
大体时间:Up to 30 months

DOR is defined as the time form the date of the first documented response (CR or PR) to the date of the first documented progression by local investigator review as per RECIST v1.1 or death due to underlying cancer.

Up to 30 months
Progression-free survival (PFS) per RECIST v 1.1
大体时间:Up to 30 months

PFS is defined as the time from the date of start of treatment to the date of the first documented progression by local investigator review as per RECIST v1.1, or death due to any cause.

Up to 30 months
Peak serum concentration (Cmax) of QEQ278
大体时间:During first 168 days of treatment

The maximum (peak) serum drug concentration after single dose administration

During first 168 days of treatment
Area under the concentration time curve (AUC) last of QEQ278
大体时间:During first 168 days of treatment

The AUC from time zero to the last measurable concentration sampling time

During first 168 days of treatment
Area under the concentration time curve (AUC) infinity of QEQ278
大体时间:During first 168 days of treatment

The AUC from time zero to infinity

During first 168 days of treatment
Time to reach peak serum concentration (Tmax) of QEQ278
大体时间:During first 168 days of treatment

The time to reach maximum (peak) serum drug concentration after single dose administration

During first 168 days of treatment
Elimination half-life (T1/2) of QEQ278
大体时间:During first 168 days of treatment

The elimination half-life associated with the terminal slope of a semi logarithmic concentration-time curve

During first 168 days of treatment
Total body clearance (CL) of QEQ278
大体时间:During first 168 days of treatment

The total body clearance of drug from the serum

During first 168 days of treatment
Volume of distribution (Vz) of QEQ278
大体时间:During first 168 days of treatment

The apparent volume of distribution during terminal phase

During first 168 days of treatment
Incidence of anti-drug antibody (ADA)
大体时间:Day 1 and 15

Immunogenicity of QEQ278

Day 1 and 15

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2023年4月4日

初级完成 (实际的)

2026年1月26日

研究完成 (实际的)

2026年1月26日

研究注册日期

首次提交

2022年7月14日

首先提交符合 QC 标准的

2022年7月14日

首次发布 (实际的)

2022年7月18日

研究记录更新

最后更新发布 (实际的)

2026年11月13日

上次提交的符合 QC 标准的更新

2026年11月9日

最后验证

2026年2月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅